Weekly Recap

Enhanced Dosing of Donanemab Lowers ARIA Risk, Anti-Tau Agent E2814 Shows Promising Results, Combination Approach of Intranasal Insulin and Empagliflozin

ByNeurologyLive® Staff

November 2nd 2024

Neurology News Network. for the week ending November 2, 2024. [WATCH TIME: 4 minutes]

Phase 3 Program of Vidofludimus Calcium Continues, CHMP Recommends Approval for Eplontersen, Patient Dosing Commenced in Phase 1/2 Trial of ATX-01

ByNeurologyLive® Staff

October 26th 2024

Neurology News Network. for the week ending October 26, 2024. [WATCH TIME: 4 minutes]

FDA Approves Lumyrz for Pediatric Narcolepsy, 24-Hour Foslevodopa/Foscarbidopa Gets FDA Greenlight, Oral Edaravone Fails in Phase 3 Study

ByNeurologyLive® Staff

October 19th 2024

Neurology News Network. for the week ending October 19, 2024. [WATCH TIME: 4 minutes]

HNSA-5487 Significantly Reduces IgG Levels, FDA Removes Hold on AOC 1001, DMD Gene Therapy Shows No Impact on Cardiac Outcomes

ByNeurologyLive® Staff

October 12th 2024

Neurology News Network. for the week ending October 12, 2024. [WATCH TIME: 4 minutes]

Horizon Study Update for MSA Drug ION464, OnaboutlinumtoxinA to be Tested in Essential Tremor, Challenges With Ketogenic-Mediterranean Diets in PD

ByNeurologyLive® Staff

October 5th 2024

Neurology News Network. for the week ending October 5, 2024. [WATCH TIME: 4 minutes]

Positive Phase 2 FORWARD-53 Data of WVE-N531, RNS60 Extends Survival in ALS, BLA to be Submitted for Deramiocel

ByNeurologyLive® Staff

September 28th 2024

Neurology News Network. for the week ending September 28, 2024. [WATCH TIME: 4 minutes]

New BREAKTHROUGH Study of BMB-101, Positive Phase 1 Data on Orexin Agonist ORX750, Dosing Commenced for QRL-101

ByNeurologyLive® Staff

September 21st 2024

Neurology News Network. for the week ending September 21, 2024. [WATCH TIME: 4 minutes]

FDA Supports A-Synuclein Assay for PD Trials, VES001 Meets Primary End Point, Digital Migraine Therapeutic CT-132 Performs

ByNeurologyLive® Staff

September 14th 2024

Neurology News Network. for the week ending September 14, 2024. [WATCH TIME: 4 minutes]

Tolebrutinib Shows Promise in Non-Relapsing Secondary Progressive MS, Fenebrutinib Suppresses Relapses in New Data, FDA Accepts Resubmitted NDA for AXS-07

ByNeurologyLive® Staff

September 7th 2024

Neurology News Network. for the week ending September 7, 2024. [WATCH TIME: 4 minutes]

AMX0035's Potential in Tauopathies, Alkermes Initiates Phase 2 Study of ALKS 2680, EryDex Falls Short in Phase 3 ATTeST Trial

ByNeurologyLive® Staff

August 31st 2024

Neurology News Network. for the week ending August 31, 2024. [WATCH TIME: 4 minutes]

Medtronic DBS Approved for Asleep Surgery, BHV-2100 Shows Early Promise, AOC 1044 Continues Dystrophin Production in Latest Update

ByNeurologyLive® Staff

August 17th 2024

Neurology News Network. for the week ending August 17, 2024. [WATCH TIME: 4 minutes]

IND Cleared for Cell Therapy in Progressive MS, FDA Approves IPX203, Migraine Treatment Nerivio Safe in Pediatric Populations

ByNeurologyLive® Staff

August 10th 2024

Neurology News Network. for the week ending August 10, 2024. [WATCH TIME: 4 minutes]

ALPHA-1062 Approved for Alzheimer Disease, GLP-1 Agonist Shows Neuroprotective Effects Against Dementia, Lecanemab 3-Year Data Reported

ByNeurologyLive® Staff

August 4th 2024

Neurology News Network. for the week ending August 3, 2024. [WATCH TIME: 4 minutes]

Cerliponase Alfa Approved for All Ages of CLN2 Disease, SAGE-324 Discontinued, ION582 to Advance to Phase 3 in Angelman Syndrome

ByNeurologyLive® Staff

July 28th 2024

Neurology News Network. for the week ending July 27, 2024. [WATCH TIME: 4 minutes]

LX2006 Improves Cardiac Biomarkers of FA, ATH434 Positive Results in MSA, Brivaracetam Effective Regardless of Intellectual Disabilities

ByNeurologyLive® Staff

July 14th 2024

Neurology News Network. for the week ending July 20, 2024. [WATCH TIME: 4 minutes]

SKY-0515 Shows Significant HTT Reduction, AMT-130 Slows Huntington Progression, Capricor to Meet With FDA on CAP-1002

ByNeurologyLive® Staff

July 14th 2024

Neurology News Network. for the week ending July 13, 2024. [WATCH TIME: 4 minutes]

AFFINITY DUCHENNE Trial Expands, Suvecaltamide Fails Phase 2b Study of Essential Tremor, PTC518 Shows Dose-Dependent Huntingtin Lowering

ByNeurologyLive® Staff

July 7th 2024

Neurology News Network. for the week ending July 6, 2024. [WATCH TIME: 4 minutes]

ABBV-951 Gets Another CRL, Pitolisant Approved for Pediatric Narcolepsy, FDA Clears Efgartigimod for CIDP

ByNeurologyLive® Staff

June 30th 2024

Neurology News Network. for the week ending June 29, 2024. [WATCH TIME: 3 minutes]

ND0612 Receives Complete Letter Response, Otsuka Terminates AVP-786, TSHA-102 Performs in Phase 1/2 REVEAL Studies

ByNeurologyLive® Staff

June 23rd 2024

Neurology News Network. for the week ending June 22, 2024. [WATCH TIME: 4 minutes]

CIFFREO Study Fails Primary End Point, Gene Therapy for Duchenne Shows Promise, Deflazacort Generic Approved by FDA

ByNeurologyLive® Staff

June 16th 2024

Neurology News Network. for the week ending June 15, 2024. [WATCH TIME: 4 minutes]

EU Approves Tofersen for SOD1 ALS, SynAIRgy Study Aims to Change OSA Treatment, FDA Approves New Dosing for Amifampridine

ByNeurologyLive® Staff

June 9th 2024

Neurology News Network. for the week ending June 9, 2024. [WATCH TIME: 4 minutes]

APN-1607 Gets Fast Track Designation, ALS Agent BIIB105 Terminated, ION582 Safe in Angelman Syndrome

ByNeurologyLive® Staff

May 25th 2024

Neurology News Network. for the week ending May 25, 2024. [WATCH TIME: 4 minutes]

Dosing Commenced in Study of Anti-Tau Agent, FDA Updates Labeling to Glatiramer Acetate Products, Eisai Initiates Rolling Submission for Subcutaneous Lecanemab

ByNeurologyLive® Staff

May 18th 2024

Neurology News Network. for the week ending May 18, 2024. [WATCH TIME: 4 minutes]

PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced

ByNeurologyLive® Staff

May 11th 2024

Neurology News Network. for the week ending May 11, 2024. [WATCH TIME: 4 minutes]

ALZ-801 Enters Open-Label Studies, Subcutaneous Ocrelizumab Gets Positive EU Recommendation, FDA Approves Sprinkle Formulation of Valbenazine

ByNeurologyLive® Staff

May 4th 2024

Neurology News Network. for the week ending May 4, 2024. [WATCH TIME: 3 minutes]

SAGE-718 Fails Phase 2 Study, Foralumab Dampens Microglial Activation, MDA and FARA Collaborate on Gene Therapy Studies

ByNeurologyLive® Staff

April 27th 2024

Neurology News Network. for the week ending April 27, 2024. [WATCH TIME: 3 minutes]

Lecanemab ARIA Rates Unaffected by Centiloid Level, AB-1005 Meets Primary End Point, Fremanezumab Safe in Obese Patients With Migraine

ByNeurologyLive® Staff

April 20th 2024

Neurology News Network. for the week ending April 20, 2024. [WATCH TIME: 3 minutes]

Cenobamate Gets New Approved Administration Routes, FDA Agrees to New Trial Design for NurOwn, ENRICH Results Published in NEJM

ByNeurologyLive® Staff

April 13th 2024

Neurology News Network. for the week ending April 13, 2024. [WATCH TIME: 3 minutes]

Amylyx Pulls ALS Drug AMX0035, Gene Therapy Shows Promise in Giant Axonal Neuropathy, Eisai Submits sBLA for New Lecanemab Dosing

ByNeurologyLive® Staff

April 6th 2024

Neurology News Network. for the week ending April 6, 2024. [WATCH TIME: 3 minutes]

NeuroVoices: Francesco Saccà, MD, PhD, on Crossing Over Dimethyl Fumarate in Friedriech Ataxia

ByMarco Meglio

April 3rd 2024

The associate professor of neurology at the University of Naples discussed a recently enrolled study assessing the use of dimethyl fumarate, an approved therapy for relapsing MS and psoriasis, in patients with Friedreich ataxia.

Weekly Recap

Enhanced Dosing of Donanemab Lowers ARIA Risk, Anti-Tau Agent E2814 Shows Promising Results, Combination Approach of Intranasal Insulin and Empagliflozin

Phase 3 Program of Vidofludimus Calcium Continues, CHMP Recommends Approval for Eplontersen, Patient Dosing Commenced in Phase 1/2 Trial of ATX-01

FDA Approves Lumyrz for Pediatric Narcolepsy, 24-Hour Foslevodopa/Foscarbidopa Gets FDA Greenlight, Oral Edaravone Fails in Phase 3 Study

HNSA-5487 Significantly Reduces IgG Levels, FDA Removes Hold on AOC 1001, DMD Gene Therapy Shows No Impact on Cardiac Outcomes

Horizon Study Update for MSA Drug ION464, OnaboutlinumtoxinA to be Tested in Essential Tremor, Challenges With Ketogenic-Mediterranean Diets in PD

Positive Phase 2 FORWARD-53 Data of WVE-N531, RNS60 Extends Survival in ALS, BLA to be Submitted for Deramiocel

New BREAKTHROUGH Study of BMB-101, Positive Phase 1 Data on Orexin Agonist ORX750, Dosing Commenced for QRL-101

FDA Supports A-Synuclein Assay for PD Trials, VES001 Meets Primary End Point, Digital Migraine Therapeutic CT-132 Performs

Tolebrutinib Shows Promise in Non-Relapsing Secondary Progressive MS, Fenebrutinib Suppresses Relapses in New Data, FDA Accepts Resubmitted NDA for AXS-07

AMX0035's Potential in Tauopathies, Alkermes Initiates Phase 2 Study of ALKS 2680, EryDex Falls Short in Phase 3 ATTeST Trial

Medtronic DBS Approved for Asleep Surgery, BHV-2100 Shows Early Promise, AOC 1044 Continues Dystrophin Production in Latest Update

IND Cleared for Cell Therapy in Progressive MS, FDA Approves IPX203, Migraine Treatment Nerivio Safe in Pediatric Populations

ALPHA-1062 Approved for Alzheimer Disease, GLP-1 Agonist Shows Neuroprotective Effects Against Dementia, Lecanemab 3-Year Data Reported

Cerliponase Alfa Approved for All Ages of CLN2 Disease, SAGE-324 Discontinued, ION582 to Advance to Phase 3 in Angelman Syndrome

LX2006 Improves Cardiac Biomarkers of FA, ATH434 Positive Results in MSA, Brivaracetam Effective Regardless of Intellectual Disabilities

SKY-0515 Shows Significant HTT Reduction, AMT-130 Slows Huntington Progression, Capricor to Meet With FDA on CAP-1002

AFFINITY DUCHENNE Trial Expands, Suvecaltamide Fails Phase 2b Study of Essential Tremor, PTC518 Shows Dose-Dependent Huntingtin Lowering

ABBV-951 Gets Another CRL, Pitolisant Approved for Pediatric Narcolepsy, FDA Clears Efgartigimod for CIDP

ND0612 Receives Complete Letter Response, Otsuka Terminates AVP-786, TSHA-102 Performs in Phase 1/2 REVEAL Studies

CIFFREO Study Fails Primary End Point, Gene Therapy for Duchenne Shows Promise, Deflazacort Generic Approved by FDA

EU Approves Tofersen for SOD1 ALS, SynAIRgy Study Aims to Change OSA Treatment, FDA Approves New Dosing for Amifampridine

APN-1607 Gets Fast Track Designation, ALS Agent BIIB105 Terminated, ION582 Safe in Angelman Syndrome

Dosing Commenced in Study of Anti-Tau Agent, FDA Updates Labeling to Glatiramer Acetate Products, Eisai Initiates Rolling Submission for Subcutaneous Lecanemab

PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced

ALZ-801 Enters Open-Label Studies, Subcutaneous Ocrelizumab Gets Positive EU Recommendation, FDA Approves Sprinkle Formulation of Valbenazine

SAGE-718 Fails Phase 2 Study, Foralumab Dampens Microglial Activation, MDA and FARA Collaborate on Gene Therapy Studies

Lecanemab ARIA Rates Unaffected by Centiloid Level, AB-1005 Meets Primary End Point, Fremanezumab Safe in Obese Patients With Migraine

Cenobamate Gets New Approved Administration Routes, FDA Agrees to New Trial Design for NurOwn, ENRICH Results Published in NEJM

Amylyx Pulls ALS Drug AMX0035, Gene Therapy Shows Promise in Giant Axonal Neuropathy, Eisai Submits sBLA for New Lecanemab Dosing

NeuroVoices: Francesco Saccà, MD, PhD, on Crossing Over Dimethyl Fumarate in Friedriech Ataxia

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

NeuroVoices: Benjamin Tolchin, MD, FAAN, on First-Ever AAN Guidelines for Functional Seizures

Women Physicians Day 2026: Sex-Specific Clinical Considerations in Women With Epilepsy

Late-Breaking CHOICE 2 Data Indicate Alteplase Displayed Improved Stroke Recovery

Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis

Biomarker Data Across Studies Support Disease-Targeted Effects of Valiltramiprosate